Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

University Hospital, Strasbourg, France260 enrolled

Overview

An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.

Study Type

OBSERVATIONAL

Enrollment

260

Conditions

Kidney Cancer

Interventions

Surgical interventionPROCEDURE

Surgical intervention with collection of tissue material

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient * Localized kidney tumors\> T1a * Patient having signed an informed consent * Patient affiliated to a health insurance plan * Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes Exclusion Criteria: * Metastatic carcinoma from the outset * Contraindication to performing a TAP CT with injection of contrast product * Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.) * Subject under legal protection * Subject under tutorship or curatorship * Pregnancy * Feeding with milk

Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts